touchIMMUNOLOGY joins Professor Marcus Maurer (Charité – Universitätsmedizin Berlin, Berlin, Germany) at EAACI 2021 to discuss the rationale behind avapritinib for advanced systemic mastocytosis and the results of the PATHFINDER study.
- Could you give us a brief overview of the disease burden of advanced systemic mastocytosis and the unmet needs in its treatment? (0:26)
- What was the rationale for investigating avapritinib in the treatment of patients with advanced systemic mastocytosis? (1:04)
- Could you tell us a little about the PATHFINDER study and its findings? (1:39)
- How clinically meaningful are these benefits? (2:35)
Disclosures: In relation to this video interview, MM has received honoraria for advice as well as institutional research support by Blueprint and Celldex.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2021 EAACI Annual Meeting.
Share this Video
Related Videos In Dermatological Diseases
Victoria P. Werth, ACR 2022: The phase 3 DeterMine trial of lenabasum in dermatomyositis
DeterMine (NCT03813160) was a phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of lenabasum for the treatment of dermatomyositis. It was a pleasure to talk with Prof. Victoria P. Werth (University of Pennsylvania, Philadelphia, PA, USA) to discuss the aims, design, eligibility criteria and findings of the phase 3 study. This information […]
Loretta Fiorillo, EADV 2022: Findings from the Phase 3 Study of Apremilast in Paediatric Plaque Psoriasis
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. touchIMMUNOLOGY were delighted to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) to discuss the the aims, design and eligibility criteria of the study investigating apremilast in paediatric patients with moderate to severe plaque psoriasis and how […]
Loretta Fiorillo, EADV 2022: Apremilast Treatment for Plaque Psoriasis in Paediatric Patients
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. It was a pleasure to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) around the unmet needs in the treatment of plaque psoriasis in paediatric patients and the clinical evidence supporting apremilast in this indication. The abstract […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!